ATE427353T1 - Heregulin varianten - Google Patents

Heregulin varianten

Info

Publication number
ATE427353T1
ATE427353T1 AT98907337T AT98907337T ATE427353T1 AT E427353 T1 ATE427353 T1 AT E427353T1 AT 98907337 T AT98907337 T AT 98907337T AT 98907337 T AT98907337 T AT 98907337T AT E427353 T1 ATE427353 T1 AT E427353T1
Authority
AT
Austria
Prior art keywords
variants
heregulin
erbb
human
provides
Prior art date
Application number
AT98907337T
Other languages
English (en)
Inventor
Marcus Ballinger
Jennifer Jones
Wayne Fairbrother
Mark Sliwkowski
James Wells
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE427353T1 publication Critical patent/ATE427353T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98907337T 1997-02-10 1998-02-10 Heregulin varianten ATE427353T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79905497A 1997-02-10 1997-02-10

Publications (1)

Publication Number Publication Date
ATE427353T1 true ATE427353T1 (de) 2009-04-15

Family

ID=25174936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98907337T ATE427353T1 (de) 1997-02-10 1998-02-10 Heregulin varianten

Country Status (11)

Country Link
US (3) US6387638B1 (de)
EP (1) EP0970207B1 (de)
JP (1) JP4515542B2 (de)
AT (1) ATE427353T1 (de)
AU (1) AU732027B2 (de)
CA (1) CA2278151C (de)
DE (1) DE69840699D1 (de)
DK (1) DK0970207T3 (de)
ES (1) ES2324320T3 (de)
IL (3) IL130827A0 (de)
WO (1) WO1998035036A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003203831B2 (en) * 1998-02-04 2006-08-10 Genentech, Inc. Use of heregulin as an epithelial cell growth factor
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
JP4485051B2 (ja) * 1998-02-04 2010-06-16 ジェネンテック， インコーポレイテッド 上皮細胞増殖因子としてのヘレグリンの用途
AU1649400A (en) * 1998-12-11 2000-07-03 Tejvir S. Khurana Neurite derived growth factors for use in the treatment of muscular dystrophy
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6825333B1 (en) * 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
AU784983B2 (en) * 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US20020165144A1 (en) * 2000-02-28 2002-11-07 Decode Genetics Ehf, Iceland Human schizophrenia gene
US7495147B2 (en) * 2000-02-28 2009-02-24 Decode Genetics Ehf. Neuregulin-1 transgenic mouse and methods of use
CA2400595A1 (en) * 2000-02-28 2001-09-07 Decode Genetics Ehf Human schizophrenia gene
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US7276605B2 (en) * 2001-02-01 2007-10-02 Roche Diagnostics Operations, Inc. Method for producing recombinant trypsin
EP1436598B1 (de) 2001-09-10 2013-11-27 Meso Scale Technologies LLC Assay-puffer, diesen enthaltende zusammensetzungen sowie diesen verwendende verfahren
AU2003218600C1 (en) 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2003237367A1 (en) * 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
US20040157770A1 (en) * 2003-02-10 2004-08-12 The United States Of America As Represented By The Department Of Veterans Affairs Method of inhibiting angiogenesis and neuroblastoma growth with alpha and beta isoforms of neu differentiation factor (NDF alpha and NDF beta)
EP2062916A3 (de) 2003-04-09 2009-08-19 Genentech, Inc. Autoimmunerkrankungstherapie eines Patienten mit unzureichender Reaktion auf einen TNF-alpha-Inhibitor
WO2005013804A2 (en) * 2003-08-05 2005-02-17 Euro-Celtique S.A. ErbB RECEPTOR METHODS AND KITS FOR MONITORING CHEMOTHERAPY RESISTANCE
KR100767583B1 (ko) * 2003-12-29 2007-10-17 엘지.필립스 엘시디 주식회사 액정표시장치 구동회로
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
KR100765496B1 (ko) 2005-12-09 2007-10-10 경희대학교 산학협력단 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물
EP3363455A1 (de) 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Verlängerte freisetzung von neuregulin für verbesserte herzfunktion
CN105802904B (zh) 2006-02-23 2021-04-20 维亚赛特公司 用于培养可分化细胞的组合物和方法
US20100215722A1 (en) * 2006-02-28 2010-08-26 Vishal Bhasin Tissue Regeneration II
WO2007109376A2 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
WO2007113366A1 (es) * 2006-04-05 2007-10-11 Consejo Superior De Investigaciones Científicas Uso de compuestos inductores del desarrollo axonal de neuronas, composiciones terapéuticas que los contienen y sus aplicaciones
EP2474556A3 (de) 2007-03-14 2012-10-17 Novartis AG APCDD1-Inhibitoren zur Behandlung, Diagnose und Erkennung von Krebs
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2346526A2 (de) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Zusammensetzungen und verfahren zur verwendung von liganden-dimeren
AU2008363829B2 (en) 2008-11-04 2014-11-20 Viacyte, Inc. Stem cell aggregate suspension compositions and methods for differentiation thereof
US8609620B2 (en) 2008-11-28 2013-12-17 Zensun (Shanghai) Science & Technology Ltd. Neuregulin peptides and their use
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2555788B1 (de) 2010-03-24 2017-10-11 Massachusetts Institute of Technology Neuregulin dimer für einen erbb/her rezeptor für die verwendung in reduzierung der kardiotoxizität
CN103118698A (zh) * 2010-05-28 2013-05-22 意识-Nrg公司 神经调节素同种型，神经调节素多肽和其使用
WO2012044612A1 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her3 antibodies
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
MX366347B (es) * 2012-08-03 2019-07-05 Cedars Sinai Medical Center Aislamiento de mutantes mejoradores del trafico de la proteina de administracion de farmaco.
AU2013248265B2 (en) 2012-11-08 2018-11-01 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
EP3610905B1 (de) 2013-05-22 2021-03-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Verlängerte freisetzung von neuregulin zur behandlung von herzinsuffizienz
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
ITUB20160828A1 (it) * 2016-02-18 2017-08-18 Univ Degli Studi Genova Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro
WO2020086667A1 (en) * 2018-10-25 2020-04-30 American University Method for promoting adipocyte differentiation and obesity-related disease treatment
MX2023014680A (es) * 2021-06-10 2024-01-12 Amgen Inc Variantes genomodificadas de la nrg-1 con una selectividad mejorada frente al erbb4 pero no frente al erbb3.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
CA2037440A1 (en) 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
NO921040L (no) 1991-03-17 1992-09-18 Yeda Res & Dev Stimulerende faktor for neu-reseptoren
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
GB9107566D0 (en) 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
GB9217316D0 (en) 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
JPH08502168A (ja) 1992-09-29 1996-03-12 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞においてイオンチャンネル誘導活性をもつ栄養因子
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
AU7042994A (en) 1993-05-21 1994-12-20 Amgen, Inc. Recombinant (neu) differentiation factors
US5670342A (en) * 1995-04-06 1997-09-23 Amgen Inc. NDF peptides
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
MX9708529A (es) * 1995-05-16 1998-02-28 Bristol Myers Squibb Co Herregulinas recombinantes y sus funciones biologicas sobre la activacion del receptor.

Also Published As

Publication number Publication date
DK0970207T3 (da) 2009-07-13
CA2278151A1 (en) 1998-08-13
IL174786A (en) 2011-12-29
US7063961B2 (en) 2006-06-20
JP2001521376A (ja) 2001-11-06
CA2278151C (en) 2010-11-16
US7563583B2 (en) 2009-07-21
WO1998035036A1 (en) 1998-08-13
AU732027B2 (en) 2001-04-12
US20030129688A1 (en) 2003-07-10
US6387638B1 (en) 2002-05-14
AU6317698A (en) 1998-08-26
EP0970207B1 (de) 2009-04-01
IL130827A0 (en) 2001-01-28
ES2324320T3 (es) 2009-08-04
US20060183194A1 (en) 2006-08-17
JP4515542B2 (ja) 2010-08-04
IL174786A0 (en) 2006-08-20
IL130827A (en) 2007-08-19
EP0970207A1 (de) 2000-01-12
DE69840699D1 (de) 2009-05-14

Similar Documents

Publication Publication Date Title
ATE427353T1 (de) Heregulin varianten
YU19903A (sh) Novi receptor nukleinskih kiselina i polipeptida
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
DE60028970D1 (de) An her2 bindende peptidverbindungen
MXPA03010747A (es) Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
YU69000A (sh) Antitela za cd23, njihovi derivati i njihove terapeutske upotrebe
PT910647E (pt) Variantes hiperactivas da dnase i humana
CY1112101T1 (el) Νευροτροφικοι παραγοντες
EP1141286A4 (de) Cytokinrezeptor-kette
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
AU7216498A (en) Inhibitors of the urokinase receptor
DK0811068T3 (da) Humane DNase I varianter
HK1150627A1 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
IL161296A0 (en) Glycosylphosphatidylinositol containing polypeptides
WO2001014415A3 (en) Egfh2 genes and gene products
MX9706429A (es) Variantes de dnasa i humana.
AU2001267433A1 (en) Nucleic acid molecules encoding a protein interacting with ser/thr kinase akt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0970207

Country of ref document: EP